Skip to content

Journal of Affective Disorders

ISSN 1573-2517, 0165-0327

260 papers in the library · 3,711 citations · publishing 2008-2026

Papers

Sort Most recent Most cited

How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.

Journal of Affective Disorders August 1, 2023 Richard J. Zeifman, Anne C Wagner, Candice M Monson et al. 56 citations

Psilocybin therapy is receiving attention as a mental health intervention with transdiagnostic potential. In line with psychotherapeutic research, qualitative research has highlighted the role of reductions in experiential avoidance (and increases in connectedness) within psilocybin therapy. However, no quantitative research has examined experiential avoidance as a mechanism underlying...

Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation.

Journal of Affective Disorders August 1, 2023 Mu-Hong Chen, Ya-Mei Bai, Hui-Ju Wu et al. 7 citations

OBJECTIVE Previous studies have found an association between klotho, an anti-aging hormone, and major depressive disorder. However, whether low-dose ketamine infusion alters klotho levels among patients with treatment-resistant depression (TRD) remains unknown. METHODS In total, 48 patients with TRD and strong suicidal ideation were randomly assigned to a single 0.5 mg/kg ketamine or 0.045...

Increased low-frequency brain responses to music after psilocybin therapy for depression.

Journal of Affective Disorders July 15, 2023 Matthew B. Wall, Cynthia Lam, Natalie Ertl et al. 36 citations

Psychedelic-assisted psychotherapy with psilocybin is an emerging therapy with great promise for depression, and modern psychedelic therapy (PT) methods incorporate music as a key element. Music is an effective emotional/hedonic stimulus that could also be useful in assessing changes in emotional responsiveness following PT. Brain responses to music were assessed before and after PT using...

The need for establishing best practices and gold standards in psychedelic medicine.

Journal of Affective Disorders July 1, 2023 Allison A. Feduccia, Gabby Agin-Liebes, Collin M. Price et al. 38 citations

Psychedelic substances are under investigation in several drug development programs. Controlled clinical trials are providing evidence for safe and effective use of psychedelic therapies for treating mental health conditions. With the anticipated FDA approval of MDMA-assisted therapy for posttraumatic stress disorder in 2023 and psilocybin therapy for depression disorders soon after, now is the...

Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study.

Journal of Affective Disorders June 1, 2023 Gustavo C. Leal, Breno Souza-Marques, Rodrigo P Mello et al.

Racemic ketamine is a mixture of (R)-ketamine (arketamine) and (S)-ketamine (esketamine), with the latter regarded as the main isomer for antidepressant effects. However, preclinical data and one open-label human trial suggest arketamine might exert a more potent and longer-lasting antidepressant effect with fewer side effects. We aimed to explore the feasibility of a randomized controlled...

A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression.

Journal of Affective Disorders May 7, 2023 Wei Zheng, Yanling Zhou, Chengyu Wang et al.

OBJECTIVES This study aims to investigate the differences in safety and antidepressant effects of multi-infusion ketamine treatment between elderly and young adults with depression. METHODS The safety, antidepressant, and anti-suicidal effects of multi-infusion ketamine were compared between 19 elderly (≥50 years) and 116 younger (<50 years) adults with depression; all were treated with six...

Unblinding and demand characteristics in the treatment of depression.

Journal of Affective Disorders May 1, 2023 Guy M. Goodwin, Megan Croal, Lindsey Marwood et al. 13 citations

Blinding of treatment allocation in clinical trials in psychiatry is regarded as an ideal. The potential impact of unblinding chimes with a general concern for psychological research: so-called demand characteristics can undermine confidence in findings from experimental and clinical studies. Scepticism can result in nihilism. The reliance on subjective report of symptoms in clinical trials of...

DOI: 10.1016/j.jad.2023.02.030 (opens in new tab) Full text (opens in new tab) Demand characteristics Unblinding Clinical-trials blinding Masking +7

Follow-up outcomes of Mindfulness-Based Cognitive Therapy (MBCT) for patients with chronic, treatment-resistant depression.

Journal of Affective Disorders May 1, 2023 Mira B. Cladder-Micus, J. Vrijsen, A. Fest et al.

BACKGROUND Mindfulness-based cognitive therapy (MBCT) is an evidence-based treatment for depression. The current study focused on the long-term effects of MBCT for chronically, treatment-resistant depressed patients during a 6-months follow-up period. Additionally, predictors of treatment outcomes were explored. METHOD The outcomes of MBCT on depressive symptoms, remission rates, quality of...

The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis.

Journal of Affective Disorders May 1, 2023 Tuuli M. Hietamies, L. Mcinnes, A. Klise et al.

INTRODUCTION Ketamine intravenous therapy (KIT) appears effective for treating depression in controlled trials testing a short series of infusions. A rapidly proliferating number of clinics offer KIT for depression and anxiety, using protocols without a strong evidence basis. Controlled comparison of mood and anxiety from real-world KIT clinics, and the stability of outcomes, is lacking....

Antenatal mobile-delivered mindfulness-based intervention to reduce perinatal depression risk and improve obstetric and neonatal outcomes: A randomized controlled trial.

Journal of Affective Disorders May 1, 2023 L. Leng, Xi-Can Yin, C. L. Chan et al.

OBJECTIVES One in five mothers will experience perinatal depression (PND) during pregnancy and within their first year following childbirth. Current evidence suggests the short-term efficacy of Mindfulness-based interventions (MBI) for perinatal women, but the extent to which this positive impact remains the early postpartum period is unclear. This study investigated the short- and maintenance...

Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.

Journal of Affective Disorders April 1, 2023 Otto Simonsson, Peter S. Hendricks, Richard Chambers et al. 124 citations

Previous studies have investigated challenging, difficult, or distressing classic psychedelic experiences, but little is known about the prevalence and associations of such experiences. Using nationally representative data of the US adult population (N = 2822), this study examined the prevalence and associations of challenging, difficult, or distressing experiences using classic psychedelics,...

Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation.

Journal of Affective Disorders April 1, 2023 Nadav Liam Modlin, Tammy M Miller, James J Rucker et al. 30 citations

Recent studies have demonstrated the promise of psilocybin therapies in creating positive changes for those with poor mental health across multiple diagnostic categories, including major depressive disorder (MDD), end-of-life anxiety, and obsessive-compulsive disorder (OCD). While there may be a large population that is eligible to participate in psilocybin therapy based on psychiatric...

DOI: 10.1016/j.jad.2023.01.077 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Optimizing psychedelics Treatment outcomes Psilocybin treatment +3

Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression.

Journal of Affective Disorders April 1, 2023 Artemis Zavaliangos-Petropulu, Shawn M. Mcclintock, Jacqueline Khalil et al. 16 citations

INTRODUCTION Ketamine treatment prompts a rapid antidepressant response in treatment-resistant depression (TRD). We performed an exploratory investigation of how ketamine treatment in TRD affects different cognitive domains and relates to antidepressant response. METHODS Patients with TRD (N = 66; 30 M/35F; age = 39.5 ± 11.1 years) received four ketamine infusions (0.5 mg/kg). Neurocognitive...

Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series.

Journal of Affective Disorders April 1, 2023 Olivier Payette, Paul Lespérance, V. D. Jodoin et al. 7 citations

BACKGROUND For individuals with treatment-resistant depression (TRD), transcranial magnetic stimulation (TMS) has become a well-established approach. In the past decade, intravenous (IV) racemic ketamine has also emerged as a potential treatment for TRD. Currently, little data is available on the clinical effects of IV racemic ketamine in TRD patients who experienced TMS-failure. METHODS...

Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis

Journal of Affective Disorders March 1, 2023 Debora de A. Simoes Moreira, Luís Eduardo Gauer, Guilherme Teixeira et al. 25 citations

Background: ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcomes (PROSPERO/CRD42022349220). Methods: We searched MEDLINE, Web of Science, Embase,...

Evaluation of clinical effects of Esketamine on depression in patients with missed miscarriage: A randomized, controlled, double-blind trial.

Journal of Affective Disorders February 28, 2023 Ming Jiang, Qianqian Li, Mingjie Mao et al.

Background: Patients with missed miscarriages are usually accompanied by varying degrees of depression, which is closely related to the patient's prognosis. We investigated whether Esketamine could alleviate postoperative depression symptoms in patients with missed miscarriages who underwent painless curettage. Methods: This study was a randomized, parallel-controlled, double-blind,...

Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients.

Journal of Affective Disorders February 15, 2023 Sarah Shnayder, Rezvan Ameli, Ninet Sinaii et al. 67 citations

While psychedelics have been shown to improve psycho-spiritual well-being, the underlying elements of this change are not well-characterized. The NIH-HEALS posits that psycho-social-spiritual change occurs through the factors of Connection, Reflection & Introspection, and Trust & Acceptance. This study aimed to evaluate the changes in NIH-HEALS scores in a cancer population with major...

DOI: 10.1016/j.jad.2022.11.046 (opens in new tab) Full text (opens in new tab) Nih-heals Psilocybin-therapy psychedelic therapy Magic mushroom treatment Cancer-mental-health cancer psychology +4

Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment.

Journal of Affective Disorders February 15, 2023 Priel Meir, Leslie Taylor, Jair C Soares et al. 25 citations

Despite psychedelic research initially ceasing in the 1970-80s, the findings documented encouraged researchers to re-examine the safety and efficacy of treating mental health with psychedelics. Of particular focus, psilocybin has shown to have therapeutic potential for a variety of mental health problems and was granted breakthrough therapy status by the FDA. Should psilocybin eventually become...

DOI: 10.1016/j.jad.2022.12.050 (opens in new tab) Full text (opens in new tab) Psychedelic-assisted therapy Barriers to treatment Mental health professionals Psilocybin-assisted therapy +5

The relationship between mindfulness and mental health among Chinese college students during the closed-loop management of the COVID-19 pandemic: A moderated mediation model.

Journal of Affective Disorders February 6, 2023 Jing Yuan, Fang Sun, Xiaomin Zhao et al.

To prevent the spread of the COVID-19 epidemic on campus, universities in outbreak areas in China can implement closed-loop management. Objects: This study aimed to explore the relationship between mindfulness and mental health of college students under closed-loop management. Measures: 11,939 college students from a university in Changsha, China participated in the online survey during the...

Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life

Journal of Affective Disorders February 3, 2023 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 168 citations

Three weeks after dosing, psilocybin 25 mg and, to a lesser degree, 10 mg improved measures of patient-reported depression severity, anxiety, affect, and functioning. These results extend the primary findings from the largest randomised clinical trial of psilocybin for TRD to examine other outcomes that are of importance to patients.

DOI: 10.1016/j.jad.2023.01.108 (opens in new tab) Anxiety Psilocybin Antidepressant Patient-reported outcomes +5

Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.

Journal of Affective Disorders February 1, 2023 Kwonmok Ko, Emma I Kopra, Anthony J. Cleare et al. 144 citations

Psychedelic therapy shows promise for Major Depressive Disorder, especially when treatment-resistant, as well as life-threatening illness distress. The objective of this systematic review, inclusive of meta-analysis, is to examine recent clinical research on the therapeutic effects of classic psychedelics on depressive symptoms. Fourteen psychedelic therapy studies, utilising psilocybin,...

Chain mediating effect of insomnia, depression, and anxiety on the relationship between nightmares and cognitive deficits in adolescents.

Journal of Affective Disorders February 1, 2023 Li-Gang Zhang, Ling-Fei Cheng, Ting-Ting Wang et al.

The study explored the differences in nightmare, insomnia, depression, anxiety, and cognitive deficits among adolescents and the chain mediating effects of insomnia, depression, and anxiety on the relationship between nightmares and cognitive deficits in adolescents. An online survey was used to collect demographic data of 6014 adolescents and assess nightmare, insomnia, depression, anxiety,...

Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial.

Journal of Affective Disorders January 6, 2023 G. Ahmed, Y. Elserogy, G. M. A. Elfadl et al. 24 citations

OBJECTIVE To evaluate the effects of ketamine treatment on depression and suicidal ideation in treatment resistant depression (TRD) and to determine whether they are influenced by other psychiatric and personality comorbidities. METHODS A randomized double-blind parallel-arm controlled study on 36 patients with TRD. Patients were divided into two treatment groups: ketamine (K group) and placebo...

Ketamine-induced hippocampal functional connectivity alterations associated with clinical remission in major depression.

Journal of Affective Disorders 2023 Fan Zhang, Chengyu Wang, Xiaofeng Lan et al.

OBJECTIVE Hippocampal functional connectivity (FC) alterations, which may happen following ketamine treatment, play a key role in major depression remission. This study aims to investigate the resting-state FC changes of the hippocampus associated with clinical remission after repeated ketamine infusions. METHODS Forty-four major depressive patients received six intravenous ketamine (0.5 mg/kg)...

Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms.

Journal of Affective Disorders December 27, 2022 Aki Nikolaidis, Rafaelle Lancelotta, Natalie Gukasyan et al. 24 citations

BackgroundSubjective experiences seem to play an important role in the enduring effects of psychedelic experiences. Although the importance of the subjective experience on the impact of psychedelics is frequently discussed, a more detailed understanding of the subtypes of psychedelic experiences and their associated impacts on mental health has not been well documented.MethodsIn the current...

DOI: 10.1016/j.jad.2022.12.042 (opens in new tab) Full text (opens in new tab) Psychedelic-assisted therapy Psychedelic experiences Psychedelic journeys Hallucinogenic experiences +20